KALV

Bullish

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KalVista Pharmaceuticals presented new data at ISPOR 2026 and the Eastern Allergy Conference, revealing the significant treatment burden and caregiver...

Business Wire 2 weeks ago 0

Bullish

KalVista CCO Sweeny sells shares worth $49,845

KalVista Pharmaceuticals CCO Nicole Sweeny sold 1,861 shares of company stock for $49,845 on May 22, 2026, primarily to cover tax obligations related ...

Investing.com 2 weeks ago 0

Neutral

KalVista (NASDAQ: KALV) CDO logs RSU vesting and small tax-driven share sale

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported exercising 3,750 restricted stock units (RSUs) and subsequently selling...

Stock Titan 2 weeks ago 0